Literature DB >> 302301

Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man.

P L Padfield, J J Morton.   

Abstract

Studies were designed to determine whether angiotensin II has a direct stimulatory effect on arginine-vasopressin in man and to determine the role, if any, played by angiotensin II in the control of vasopressin release in physiological and pathological conditions. Acute infusion of angiotensin II in normal volunteers produced small but definite increases in plasma levels of arginine-vasopressin (5-4+/-0-3(S.E.M.) to 6-4+/-0-2 pg/ml) only when plasma angiotensin II levels were supraphysiological. Concurrent measurements of plasma arginine-vasopressin and angiotensin II were made during acute changes in fluid balance and posture in normal volunteers and in clinical conditions characterized by high plasma levels of angiotensin II (Addison's disease and Bartter's syndrome). The results of these studies allow us to conclude that there is little to suggest a direct effect of angiotensin II which is likely to be relevant to the normal physiological control of arginine-vasopressin in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302301     DOI: 10.1677/joe.0.0740251

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

1.  Glucagon increase after chronic AT1 blockade is more likely related to an indirect leptin-dependent than to a pancreatic α-cell-dependent mechanism.

Authors:  Martin Mildner; Helge Müller-Fielitz; Ines Stölting; Olaf Jöhren; Muscha Steckelings; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-31       Impact factor: 3.000

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol.

Authors:  S Sonkodi; E Agabiti-Rosei; R Fraser; B J Leckie; J J Morton; A M Cumming; V P Sood; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

Authors:  A Ohnishi; Y Orita; R Okahara; H Fujihara; T Inoue; Y Yamamura; Y Yabuuchi; T Tanaka
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

5.  Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans.

Authors:  M C Petrie; J E McDonald; C Hillier; J J Morton; J J McMurray
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

6.  Strength training attenuates post-infarct cardiac dysfunction and remodeling.

Authors:  Michael A Garza; Emily A Wason; Justin R Cruger; Eunhee Chung; John Q Zhang
Journal:  J Physiol Sci       Date:  2019-03-25       Impact factor: 2.781

7.  [Effect of saralasin on plasma renin activity and arginine-vasopressin in patients with angiotensin-dependent hypertension (author's transl)].

Authors:  I P Arlart; H Wagner; J Rosenthal
Journal:  Klin Wochenschr       Date:  1978-06-15

8.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Authors:  J G Cleland; H J Dargie; S G Ball; G Gillen; G P Hodsman; J J Morton; B W East; I Robertson; I Ford; J I Robertson
Journal:  Br Heart J       Date:  1985-09

Review 9.  Bioactive peptides from muscle sources: meat and fish.

Authors:  Joseph Thomas Ryan; Reynolds Paul Ross; Declan Bolton; Gerald F Fitzgerald; Catherine Stanton
Journal:  Nutrients       Date:  2011-08-31       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.